Why is Wegovy not covered by insurance? Wegovy is not covered by many insurance plans because it's excluded from their formulary (approved drug list). This doesn't mean you can't get coverage—you can request a formulary exception with proper documentation.
What to do if Wegovy is not covered by your insurance:
- 1. Confirm WHY it's not covered (formulary exclusion vs. other denial)
- 2. Request a formulary exception with a Letter of Medical Necessity
- 3. Document why alternatives (like Zepbound) don't work for you
- 4. If denied, appeal—39-59% of GLP-1 appeals succeed with human review[10]
WHO THIS GUIDE IS FOR: Patients who found out Wegovy is not covered by their insurance, received a "not on formulary" denial, or want to understand their coverage options.
UNDERSTANDING YOUR DENIAL
What Does 'Wegovy Not Covered by Insurance' Mean?
When your insurance says Wegovy is not covered, it typically means one of three things:
| Type of "Not Covered" | What It Means | Can You Get Coverage? |
|---|---|---|
| Formulary Exclusion | Wegovy isn't on your plan's approved drug list | Yes—request a formulary exception |
| Weight Loss Drug Exclusion | Your plan excludes ALL weight loss medications | Harder, but possible via cardiovascular (CV) indication or employer advocacy |
| Prior Authorization Denied | Drug IS on formulary but you didn't meet criteria | Yes—appeal the denial |
Check Your Denial Letter
Your denial letter will specify WHY Wegovy is not covered. Look for phrases like "not on formulary," "excluded benefit," or "does not meet medical necessity." This determines your next steps.
The good news: Even when Wegovy is not covered by insurance initially, many patients successfully get coverage through exception requests and appeals. This guide shows you how.
UNDERSTANDING FORMULARY EXCLUSIONS
Why Wegovy May Not Be on Your Formulary
The Coverage Gap
If your plan says Wegovy is not covered by insurance, it usually means the drug is excluded from your formulary—but patients can still request a medical exception. As of 2025, over 28 million Americans lack commercial insurance coverage for Wegovy, with 75% of those who do have coverage facing restrictions like prior authorization.[1]
A formulary exclusion means Wegovy isn't on your insurance plan's drug list. Your plan's "formulary" is simply the list of medications it will pay for. When a drug is excluded, your insurer won't cover it—even with approval—unless you ask for an exception.
Here's why Wegovy may be excluded from your plan:
Your plan excludes weight loss medications entirely
Many employers and insurance plans have a blanket exclusion for all weight loss drugs. This is a common reason for Wegovy denials—the plan simply doesn't cover any medications prescribed for weight management, regardless of medical necessity or FDA approval.
Your PBM chose a different preferred medication
A PBM (Pharmacy Benefit Manager) is the company that manages your drug coverage. PBMs negotiate prices with drug makers. Your PBM may have gotten a better deal on Zepbound than on Wegovy. That makes Zepbound "preferred" and Wegovy excluded—or vice versa.
Note: CVS Caremark actually prefers Wegovy over Zepbound as of July 2025.[2] If you have CVS Caremark and were denied, check if you were prescribed Wegovy specifically.
Cost management decisions
GLP-1 medications (a class of weight loss drugs) like Wegovy cost over $1,000/month without insurance. As demand for these drugs has surged, many plans have tightened coverage or excluded them entirely to control costs. This is a business decision, not a medical one.
Medicare Part D restrictions
If you have Medicare Part D: by federal law, basic Part D coverage excludes drugs used for weight loss, but the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), which runs outside the Part D benefit, covers Wegovy for weight loss for $50 per monthly fill if you meet CMS’s criteria and your prescriber gets prior authorization. Wegovy also has a cardiovascular (CV) indication (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)) for adults with established cardiovascular disease and either obesity or overweight; prescribed for that use, it may be covered under Part D, subject to the plan’s formulary, prior authorization and exceptions process.[3]
Is Wegovy Covered by Insurance If It's Not on the Formulary?
A formulary exclusion doesn't mean you can't get Wegovy covered. You can request a formulary exception—and if you have documentation showing why formulary alternatives don't work for you, you may succeed. Many patients win coverage even when Wegovy isn't on their plan's drug list.
Your GLP-1 coverage,
denied approved
Honest Care writes personalized, evidence-backed appeal letters — so you can fight back with confidence.
Need help with your exception request?
Get Started FreeNEXT STEPS
How to Request a Formulary Exception
You can request a formulary exception by having your doctor submit a Letter of Medical Necessity explaining why Wegovy is required. You have 180 days from your denial date to file.
For the complete step-by-step appeal process, see our Wegovy Appeals Guide.
KEY DOCUMENTATION
What to Include in Your Exception Request
The Most Important Factor
The #1 reason exception requests succeed is documented failure or intolerance of formulary alternatives. If you've tried Zepbound and it didn't work or caused side effects, that's your strongest argument for Wegovy coverage.
Your exception request should include:
What to Include
- Your information: Full name, date of birth, insurance ID, case number
- Your diagnosis: Obesity or overweight with other health conditions
- Weight history: Your current weight and how it's changed over time
- What you've tried: Past diets, exercise programs, and weight loss drugs
Why Covered Drugs Don't Work for You
This is the key part. You need to show why drugs your plan does cover (like Zepbound) won't work:
| Reason | Documentation Needed |
|---|---|
| It didn't work | Records showing you tried Zepbound but didn't lose enough weight |
| Bad side effects | Doctor's notes showing Zepbound made you sick (nausea, vomiting, etc.) |
| Can't take it safely | A health condition means you shouldn't take Zepbound |
| Already on Wegovy | If it's working for you, switching could hurt your progress |
Research That Supports Wegovy
Your doctor can cite these peer-reviewed studies to justify why Wegovy is medically necessary:
- STEP-1 trial (NEJM): 15% average weight loss at 68 weeks. 83% of patients lost ≥5%, 66% lost ≥10%, and 48% lost ≥15%—far exceeding the ≥5% threshold insurers require.[4]
- SELECT trial (NEJM): 20% reduction in major heart events (heart attack, stroke, CV death) in 17,604 patients over ~40 months. This is the largest CV outcomes trial for any weight loss medication.[5]
- Cardiovascular indication: The FDA approved Wegovy to reduce CV risk in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets))—the first weight-loss medication approved to reduce cardiovascular risk (FDA, March 8, 2024, Wegovy injection). This is a key differentiator from Zepbound for exception requests.[3]
TEMPLATE TO USE
Sample Formulary Exception Letter
Use this structure for your formulary exception request. Your provider should customize it with your specific medical details:
View Formulary Exception Letter Template
HEADER:
[Date] [Insurance Company/PBM Medical Director] [Address] Re: Formulary Exception Request for [Patient Name] Member ID: [Number] DOB: [Date] Requested Medication: Wegovy (semaglutide—the active ingredient)
OPENING:
"Dear Medical Director, I am writing to request a formulary exception for Wegovy (semaglutide) for my patient, [Patient Name], who has been diagnosed with [obesity/overweight with comorbidities]. I understand that Wegovy is not currently on [Insurance Plan]'s formulary. However, I believe Wegovy is medically necessary for this patient because formulary alternatives are inappropriate for the following reasons."
PATIENT HISTORY:
• Current BMI (body mass index): [X] kg/m² (weight: [X] kg, height: [X] cm) • Weight history: [describe progression over past 1-2 years] • Comorbid conditions (other health problems): [list with ICD-10 codes—standard diagnosis codes used by insurers] • Prior treatment attempts: [list all diets, programs, medications with dates and outcomes]
WHY FORMULARY ALTERNATIVES ARE INAPPROPRIATE:
"[Patient] previously tried [Zepbound/other formulary drug] from [dates]. The patient experienced [inadequate weight loss of only X% / severe side effects including... / was contraindicated due to...]. Documentation attached. Given this treatment history, continuation with formulary alternatives is not clinically appropriate."
CLINICAL RATIONALE FOR WEGOVY:
"Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition. In the STEP-1 trial, semaglutide achieved weight loss of up to 14.9% at 68 weeks. Additionally, Wegovy is FDA-approved to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight—the first weight-loss medication approved to reduce cardiovascular risk (FDA, March 8, 2024, Wegovy injection). [Patient]'s cardiovascular history makes this especially relevant."
CLOSING:
"Based on the clinical evidence and this patient's treatment history, I respectfully request that [Insurance Plan] approve a formulary exception for Wegovy. Without effective pharmacotherapy, [Patient] faces ongoing health risks including [list specific risks]. Please contact me at [phone] with any questions or to schedule a peer-to-peer discussion. Sincerely, [Provider Name, Credentials] [NPI Number—your provider's unique identifier]"
Official resource: Contact NovoCare at 1-888-809-3942 for coverage assistance and support resources.[6]
2025-2026 COVERAGE STATUS
Which Insurers Commonly Exclude Wegovy
Coverage Landscape
As of 2025, over 28 million Americans lack commercial insurance coverage for Wegovy. Of those who do have coverage, 75% (about 3 out of 4 people) face restrictions like prior authorization (pre-approval from your insurer) or step therapy (must try other medications first).[1]
Here's the current status of major insurers and PBMs (pharmacy benefit managers):
| Insurer/PBM | Wegovy Status | Notes |
|---|---|---|
| CVS Caremark | Preferred | Wegovy is PREFERRED over Zepbound as of July 2025. Prior auth required.[2] |
| Express Scripts | Varies by plan | Coverage depends on specific employer plan. Check your formulary.[7] |
| OptumRx | Varies by plan | UHC commercial plans often cover with prior auth.[8] |
| UnitedHealthcare | Varies by plan | Coverage depends on employer plan. Prior auth required when covered. |
| Aetna | Varies by plan | Requires 6 months in weight management program. Prior auth required. |
| Blue Cross Blue Shield | Varies by state/plan | Some BCBS plans exclude all weight loss drugs. Check your specific plan. |
| Kaiser Permanente | Varies by region | Often requires step therapy (trying other meds first). |
| ACA Marketplace (Obamacare) | Rarely covered | Only 1% of Marketplace plans cover Wegovy for weight loss.[9] |
| Medicare Part D | CV indication only | Basic Part D excludes weight-loss drugs (the separate Medicare GLP-1 Bridge covers weight loss, with conditions); Wegovy may be covered for CV risk reduction, subject to the plan’s formulary, prior authorization and exceptions process.[3] |
How to check your coverage:
- Log into your insurance portal and search the formulary/drug list
- Call the member services number on your insurance card
- Ask your pharmacy to run a test claim
For comprehensive coverage information, see our guide on Wegovy insurance coverage.
ALTERNATIVE PATHWAYS
What If Your Exception Is Denied?
Most Patients Never Appeal—But Those Who Do Often Win
39-59% of GLP-1 appeals succeed—yet 85% of patients never file an appeal, and 69% don't even know they can.[10] When appeals receive human review instead of automated denial, success rates reach ~49%. Insurance companies rely on patients giving up. Don't be one of them.
Related: Appeal Guide · Prior Auth Checklist · Cost Without Insurance
Option 1: Appeal the Denial
If your formulary exception is denied, you have the right to appeal:
- Internal appeal: Request reconsideration with additional documentation
- Peer-to-peer review: Your doctor speaks directly with the insurance medical director
- External review: An independent reviewer evaluates your case (decision is binding)
See our full Wegovy appeals guide for step-by-step instructions.
Option 2: Try the Formulary Alternative First
If you haven't tried Zepbound yet, your insurer may require you to try it before approving Wegovy. While this is frustrating, documented failure on Zepbound becomes strong evidence for your exception request.
Option 3: Request Coverage for the Cardiovascular Indication
Your plan may exclude weight loss medications but cover drugs for cardiovascular risk reduction. Wegovy has a unique advantage here:
- Cardiovascular risk reduction — Wegovy is FDA-approved to reduce heart attacks and strokes in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)). It is the first weight-loss medication approved to reduce cardiovascular risk (FDA, March 8, 2024, Wegovy injection).[3]
- Medicare coverage pathway — If you have Medicare, established cardiovascular disease and obesity or overweight, your doctor can prescribe Wegovy for CV risk reduction (not weight loss); it may be covered under Part D, subject to the plan’s formulary, prior authorization and exceptions process.
Note: Zepbound is FDA-approved for obstructive sleep apnea (OSA), but Wegovy is not. If you need sleep apnea treatment specifically, Zepbound may be a better option for that indication.
Option 4: Talk to Your Employer
If you have employer-sponsored insurance, contact your HR department. Some employers can advocate for coverage exceptions or add GLP-1 medications to the plan at the next renewal.
Option 5: Pay Out of Pocket
If insurance won't cover it, you still have options:
- Wegovy Savings Card: Pay as little as $25/month if your commercial insurance covers Wegovy (effective January 2, 2026)[6]
- NovoCare Self-Pay: $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026, then $349/month ($399 for Wegovy HD 7.2 mg)[6]
- Oral Wegovy: The new pill form costs $149–$299/month by dose through NovoCare[11]
- Patient assistance: Wegovy is not on Novo Nordisk’s Patient Assistance Program list; see our guide for other options
For cost assistance options, see our Wegovy cost guide.
COMMON QUESTIONS ABOUT FORMULARY EXCLUSIONS
Frequently Asked Questions
There are several reasons Wegovy may not be covered:
- Plan exclusion: Your plan may exclude all weight loss medications.
- PBM decision: Your pharmacy benefit manager chose a competitor like Zepbound instead.
- Employer choice: Your employer didn't include GLP-1 (weight loss drug) coverage.
- Medicare limits: by law, basic Medicare Part D coverage excludes drugs used for weight loss; the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), which runs outside Part D, covers Wegovy for $50 per monthly fill if you meet CMS’s criteria and your prescriber gets prior authorization.
You may still get coverage through a formulary exception, appeal, or the cardiovascular indication (if you have established cardiovascular disease and obesity or overweight).
A formulary exclusion means the drug is not on your plan's list of covered medications. Your plan's "formulary" is simply the approved drug list. Your plan won't pay for an excluded drug unless you ask for an exception and get approved.
Prior authorization: The drug IS on your plan's list, but you need pre-approval first.
Formulary exception: The drug is NOT on the list. You're asking your plan to cover it anyway. This is harder and needs more documentation.
It depends on your plan type. Individual and small-group ACA plans must decide within 72 hours (24 hours if urgent), and Medicare Part D uses the same 72-hour/24-hour exception timelines. Large-group and self-funded employer plans follow their own exception process; federal claims rules allow up to 15 days (72 hours if urgent). Your doctor can request urgent review.
If your plan excludes all weight loss drugs, getting Wegovy covered for weight loss will be very hard. But Wegovy is also approved to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets))—the first weight-loss medication approved to reduce cardiovascular risk (FDA, March 8, 2024, Wegovy injection). If that describes you, your doctor might prescribe it for CV risk reduction, which some plans may cover under their own criteria (under Medicare, Part D coverage is subject to the plan's formulary, prior authorization and exceptions process).
Yes! You have the right to appeal. You can:
- Send more documentation and try again (internal appeal)
- Ask for a peer-to-peer call (your doctor talks to their medical director)
- Request an outside review by an independent reviewer (external appeal)
The outside review decision is final—the insurer must accept it.
YOUR PATH FORWARD
What's Next
Ready to Appeal?
39-59% of GLP-1 appeals succeed—and that number jumps to ~49% when appeals get human review instead of automated denial.[10] Our complete Wegovy appeals guide walks you through the entire process—from writing your appeal letter to requesting external review.
Other Common Denial Reasons
Denied for a different reason? See our guides for other denial types:
- Medical Necessity Not Met — Insurer says treatment isn't needed
- Step Therapy Required — Must try other medications first
- BMI Criteria Not Met — Weight thresholds not satisfied
Not sure why you were denied? View all Wegovy denial types
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedWHAT'S CHANGING
Formulary Exclusions: 2026 Outlook
2026: Mixed Changes—Some Gains, Some Losses
The Wegovy coverage landscape is shifting in both directions. Good news: CVS Caremark prefers Wegovy, oral Wegovy launched, and Medicare CV coverage is expanding. Bad news: California Medi-Cal and Pennsylvania Medicaid ended Wegovy coverage for weight loss as of January 1, 2026.
Last updated October 6, 2026
Oral Wegovy Now Available
The FDA approved oral Wegovy (semaglutide tablet) on December 22, 2025—the first oral GLP-1 approved for weight loss. NovoCare self-pay pricing:[11]
- 1.5mg tablets: $149/month; 4mg tablets: $199/month
- 9mg and 25mg tablets: $299/month
This provides a more affordable self-pay option if your insurance excludes injectable Wegovy.
Medicare CV Indication Coverage
While basic Medicare Part D coverage excludes weight-loss drugs (the Medicare GLP-1 Bridge is separate), Wegovy's cardiovascular indication (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)) opens a possible coverage pathway:
- Coverage depends on the plan’s formulary, prior authorization and exceptions process
- Requires established cardiovascular disease + obesity or overweight
- Prescription must be for CV indication, not weight loss
Note: TrumpRx launched February 5, 2026. TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price): for Wegovy, NovoCare self-pay pricing ($349/month ($399 for Wegovy HD 7.2 mg)).
State Medicaid Changes (January 2026)
Several states have ended or restricted Wegovy coverage for weight loss:
- California Medi-Cal: Ended Wegovy coverage for weight loss effective January 1, 2026. Coverage continues for MASH (metabolic liver disease) or cardiovascular disease with prior authorization.[12]
- Pennsylvania Medicaid: Ended adult (21+) coverage for GLP-1s including Wegovy for weight loss effective January 1, 2026. New authorizations required for all users.[12]
- GEHA (Federal employees): Moved Wegovy to non-preferred status in 2026, potentially increasing out-of-pocket costs. (Check your plan's formulary for current status.)
If you have Medicaid and need Wegovy, ask your doctor about the cardiovascular indication pathway or check if you qualify for the diabetes indication (Ozempic, same ingredient).
Exception Requests Remain an Option
Even with formulary exclusions, you can request exceptions. Federal rules require plans to:
- Decide exception requests within 72 hours (24 hours if urgent) in individual and small-group ACA plans
- Employer plans follow their own exception process (up to 15 days under federal claims rules, 72 hours if urgent)
- Provide specific reasons for denials
- Explain the appeal process clearly
ACA and ERISA plans must allow at least 180 days for an internal appeal; your denial letter states your plan’s exact deadline (Medicare plans differ). Don't wait—file as soon as you receive your denial.
Formulary Exclusion Denials for Other GLP-1s
Similar formulary denial? The appeal strategies are comparable across medications:
References
- GoodRx/MMIT. (2025). "Insurance Coverage for GIP and GLP-1 Agonists." Over 28 million Americans lack commercial coverage for Wegovy; 75% of covered lives face restrictions. https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
- Truveta Research. (September 2025). "Impact of the CVS GLP-1 formulary change: Trends in prescribing." CVS Caremark prefers Wegovy over Zepbound as of July 2025. https://www.truveta.com/blog/research/research-insights/impact-of-the-cvs-glp-1-formulary-change-trends-in-prescribing
- U.S. Food and Drug Administration. (March 8, 2024). "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. STEP 1 trial. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. SELECT trial: 20% MACE reduction. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- NovoCare. (January 2026). "Wegovy Savings Card and Coverage Support." Savings offer for commercially insured patients (effective Jan 2, 2026) and self-pay pricing. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- Evernorth/Express Scripts. (July 2025). "Express Scripts expands Patient Assurance Program." Optional GLP-1 cost cap that employers can add: $200/month cap (only if your employer adds it). https://www.evernorth.com/articles/express-scripts-expands-patient-assurance-program-drive-affordability-and-access-glp-1s
- UnitedHealthcare. (2025). "Prior Authorization and Step Therapy." Coverage varies by employer plan; most commercial plans require PA for GLP-1s. https://www.uhc.com/member-resources/health-care-programs/prior-authorization
- Kaiser Family Foundation. (2024). "Insurer Strategies to Control Costs Associated with Weight Loss Drugs." Only 1% of Marketplace plans cover Wegovy. https://www.kff.org/health-costs/insurer-strategies-to-control-costs-associated-with-weight-loss-drugs/
- Honest Care / Counterforce Health / IvyRx. (2025). GLP-1 appeal statistics compilation. Internal appeals succeed 39-59% with human review; 85% of patients never file appeals; 69% don't know they can appeal. Sources: Honest Care, Counterforce Health, IvyRx
- Wegovy.com / GoodRx. (January 2026). "Oral Wegovy Pricing." Self-pay pricing by dose. https://www.wegovy.com/about-wegovy/the-wegovy-pill.html
- State Medicaid policy changes. (January 2026). California DHCS and Pennsylvania DHS announced ending GLP-1 weight loss coverage effective January 1, 2026. Coverage continues for CV disease or MASH indications with prior authorization. CA DHCS Pharmacy
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.